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Stroke results from a transient or permanent reduction in blood flow to the brain. The mechanisms involving neuronal death following ischemic
insult are complex and not fully understood. One signal which may control ischemic neuronal death is the inappropriate activation of cell cycle
regulators including cyclins, cyclin dependent kinases (CDKs) and endogenous cyclin dependent kinase inhibitors (CDKIs). In dividing cells,
activation of cell cycle machinery induces cell proliferation. In the context of terminally differentiated-neurons, however, aberrant activation of
these elements triggers neuronal death. Indeed, there are several lines of correlative and functional evidence supporting this “cell cycle/neuronal
death hypothesis”. The objective of this review is to summarize the findings implicating cell cycle machinery in ischemic neuronal death from in
vitro and in vivo studies. Importantly, determining and blocking the signaling pathway(s) by which these molecules act to mediate ischemic
neuronal death, in conjunction with other targets may provide a viable therapeutic strategy for stroke damage.
© 2006 Elsevier B.V. All rights reserved.Keywords: Stroke; CDKs; Cyclins; Cell cycle; Apoptosis1. Introduction
Stroke occurs primarily as a result of a transient or permanent
interruption of blood supply to the brain. This condition can
stem from an occluded or ruptured blood vessels and in some
cases cardiac arrest. Consequently, neurons in the affected brain
region, or the whole brain in the case of a cardiac arrest, are
deprived of oxygen and glucose. This sets in motion a cascade
of cellular activities that ultimately culminate in neuronal cell
death [1–3].
Presently, stroke is a leading cause of death and permanent
disability in industrialized nations. Stroke occurs on average
every 45 seconds in the USA (www.strokecenter.org). The
American Heart Association (AHA) estimates the cost of
treating stroke related injury and disability at $58 billion for
2006 alone (www.americanheart.org). Currently the treatment
of stroke is mainly reliant on the use of thrombolytics such as
tissue plasminogen activator (TPA), which themselves can pose
an inherent risk of intracerebral hemorrhage. This limits the use
of TPA to only certain cases of stroke. Furthermore, the efficacy⁎ Corresponding author. Tel.: +1 613 562 5800x8269; fax: +1 613 562 5403.
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doi:10.1016/j.bbadis.2006.11.009of TPA depends on timely presentation of <3 h which excludes
95% of stroke patients [4,5]. Thus there is a need to develop
new and efficacious neuroprotective strategies for the treatment
of stroke.
The development of new strategies for stroke hinges on
better understanding of the complex cellular and molecular
interplay that ensue following stroke. A maelstrom of
dyregulated molecules and potential perpetrators of ischemic
neuronal death have been recently suggested. One of these
exciting new developments involves the role of cell cycle
molecules such as the cyclin dependent kinases. The notion that
cell cycle machinery may mediate ischemic neuronal death is
not unique to stroke. Indeed research evidence from numerous
labs have demonstrated correlative relationship between the
dysregulation of cell cycle machinery and neuronal death
models of neurodegenerative diseases such as Parkinson's
disease (PD) [6,7], Alzheimer's disease (AD) [8–10], amyo-
trophic lateral sclerosis (ALS) [11,12], and Niemann–Pick type
C disease [13,14]. Whether or not cell cycle mechanism is
similar in neurodegenerative diseases and acute conditions such
stroke is unknown. This review will focus only on evidence
implicating cell cycle molecules in ischemic neuronal death. We
will also briefly discuss the potential involvement of other
members of the CDK family not directly involved in cell cycle
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in stroke.
2. Ischemic neuronal death
The mechanism(s) of ischemic neuronal death is complex
and may be determined by factors such as the location, severity
and duration of insult. For example, neuronal death in the
ischemic core, the region most severely affected by the lack of
blood flow, occurs within minutes to a few hours and is marked
predominantly by necrotic and excitotoxic cell death. Neuronal
death in the ischemic penumbra, the region less severely
affected by ischemia, is marked mainly by delayed apoptotic-
like death that can progress over a period of days.
The precise sequence of events leading to neuronal death
following stroke is at present not fully defined. However, a core
picture is developing. Following the disruption of blood flow,
the affected brain region(s) undergo a period of hypoxia
resulting in a decrease in cellular ATP, due primarily to impaired
mitochondrial oxidative respiration, a process that generates
majority of the cellular energy required to maintain proper cell
functions. The reduction of cellular energy results in the
impairment of vital cellular functions such as the maintenance
of the Na+/K+ pump, massive depolarization and excessive
release of glutamate. Over activation of the glutamate channel
particularly the N-methyl-D-aspartate receptor (NMDAR)-type
channels mediates massive influx of Ca2+ resulting in cellular
excitotoxicity and neuronal death. Increase in intracellular free
calcium results in the activation of Ca2+ sensitive enzymes such
as calpains proteases which then act to activate other molecules
and cleave cellular structures. In addition to the events describe
above other stressors such as oxidative stress, and DNA damage
have been demonstrated to mediate ischemic neuronal death.
Furthermore, extrinsic stressors such as the activation of glialFig. 1. Schematic representation of our current understanding of the mammalian ce
duplication. Each phase of the cell cycle is regulated by different complement of cycl
downstream target, the retinoblastoma gene product. pRb is sequentially phosphoryla
This results in the transcription of E2F responsive genes and those required for thecells and inflammation may impinge on ischemic neurons to
mediate their demise. These later findings are particularly
relevant when it comes to therapeutic interventions. In fact, cell
cycle regulation may also play a critical role with these non-
neuronal cell types in brain injury [15,16]. However, we will not
mention this further in this review, but will instead focus on how
the cell cycle machinery may impact neurons more directly.
3. Cell cycle regulation
Cell cycle is a highly regulated process. Timing progression
of cell cycle through different phases, G0, G1 S, G2, and M
requires an orchestrated functions of several elements, including
cyclins, cyclin-dependent kinases (CDKs), retinoblastoma
protein (Rb; pocket proteins) and E2F complex proteins [17].
Different complexes of cyclin-CDK drive each phase of cell
cycle [18]. In this regard, the current model is that cyclin D–
cdk4/6 and cyclin E–cdk2 complexes regulate G1/S progres-
sion, cyclin A–cdk2 complexes mediate S/G2 transitions, and
cyclin B–cdc2 complexes mediate M-phase progression
[19,20]. In addition, a recent report has suggested that cyclin
C–cdk3 complexes also regulate G0/G1 transition [21] (Fig. 1).
CDKs activity is regulated by binding to activating cyclin
partners [22] as well as endogenous CDK inhibitors such as
members of the INK4 (p15, p16, p18, p19) and Cip/Kip (p21,
p27, p57) families [23,24]. Finally, phosphorylation also plays a
critical role in CDK regulation. For example, cyclin H–cdk7–
Mat1 (Cdk Activating Kinase; CAK complex) by phosphoryla-
tion of a central threonine [25] and cdc25 by dephosphorylation
of thr14 (on cdc2) or tyr15 (on cdk2) modulate CDKs
conformation to a fully active structure so they recognize their
substrates more efficiently [23]. CDKs mediate cell cycle
progression by phosphorylating downstream targets [26]. For
example, an important target of G1 CDKs is the tumorll cycle. The cell cycle is broadly divided into four phases culminating in cell
in dependent kinases together with a cognate cyclin. During the G1/S-phase, the
ted by the G1 CDKs resulting in the release of E2F transcription factor and DP.
progression thorough S-phase.
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phosphorylated by cyclin D1–cdk4/6 and cyclin E–cdk2
complexes. Once hyperphosphorylated, Rb repression of E2F
containing complexes is alleviated. E2F, along with a required
binding partner DP activate genes required for S phase
progression [28–30].
A growing body of exciting evidence indicates that CDKs
may have a function beyond its canonical role in cell cycle
regulation. Indeed, it has been suggested that neuronal death
may be controlled by the inappropriate activation of some of
cell cycle elements [31]. The hypothesis, compatible with the
general cell cycle/neuronal death notion, is that activation of
these regulatory elements, in the context of post-mitotic
neurons, signals for death rather than cell cycle progression.
Several lines of in vitro and in vivo evidence support this
hypothesis that aberrant activation of cell cycle involves in
different pathological conditions such as stroke [32–34] , AD
[35], PD [6,7] , ALS [11].
In this review, we will first start our discussion with
deregulation/upregulation of cell cycle regulators in in vitro
paradigms of ischemic neuronal death and then will provide in
vivo evidence suggesting that cell cycle might control death
following ischemic neuronal injury in the adult animal. Finally,
we will touch upon the role of other CDKs, in particular the
neuronal cdk5 which has important roles in neuronal develop-
ment and death and which might also link to cell cycle signals.
4. In vitro evidence for involvement of cell cycle elements in
stroke
Generally, terminally differentiated cells such as neuron do
not divide. Indeed as neurons undertake the process of terminal
differentiation they irreversibly withdraw from the cell cycle.
The levels and activity of key cell cycle regulators are
downregulated in differentiated neurons [36,37]. For example,
Cdk4, a regulator of G1/S transition becomes increasingly
associated with the CDK inhibitor p27 and its activity declines
in parts due to loss of phosphorylation by its activator CAK
[36]. Similarly, the levels and activity of cdk2 another important
regulator of the G1/S is downregulated in differentiated
neurons. Consequently, the levels of hypophosphorylated Rb
increases resulting in greater E2F1 sequestration [36]. Silencing
E2F1 in neurons is particularly important since its over-
expression promotes aberrant S-phase entry in neurons [38].
Furthermore, overexpression of E2F1 alone in the context of a
post-mitotic neuron and in the absence of insult induces
neuronal death [38,39]. Downregulation of cell cycle machinery
and inhibition of E2F1 activity through its sequestration by Rb
is thus an important feature of terminally differentiated neurons.
This is underscored by observations that overexpression of Rb
or the CDK inhibitor p27 is sufficient to induce neuronal
differentiation [36]. In addition to downregulation of CDK
levels and activity, observations by Sumrejkanchanakij et al.
[40] suggests that the cell cycle may be held in check in post-
mitotic neurons through cellular redistribution of cell cycle
components. For example, in undifferentiated neurons cyclin
D1 appears both cytoplasmic and nuclear but becomes pre-dominantly cytoplasmic in differentiated neuroblastoma and
cortical neurons [37,40]. Ectopic expression of cyclin D1 in
differentiated neurons leads to cytoplasmic sequestration
whereas forced nuclear expression by fusing to a nuclear
localization signal induces apoptosis [37]. This suggests that
cellular redistribution of cell cycle machinery is an important
aspect in the maintenance of quiescent state in adult neurons.
While the above evidence indicates what happens under normal
developmental conditions, accumulating research evidence also
suggests that cell cycle machinery are activated in adult neurons
in response to numerous stressors such as DNA damage, NGF
deprivation, proteosome inhibition and â-amyloid toxicity and
models of ischemic neuronal death [39,41–47].
In regards to the latter type of injury, multiple lines of
evidence in vitro suggest a role for cell cycle regulators as
mediators of ischemic injury. Firstly, Katchanov and collea-
gues [42] reported lose of the CDK inhibitor p27 following
oxygen glucose deprivation (OGD) of neocortical neurons.
This group also reported increases in cyclin D1 protein levels
and activation of cdk2 following OGD [42]. Similar increase
in cyclin D1, cyclin E, and cdk2 is observed following kainic
acid (KA) induced death in cerebellar granule neurons (CGNs)
[48,49]. Secondly, Rb, a downstream target of cyclinD/Cdk4
is increasingly phosphorylated following hypoxia/reoxygena-
tion and KA induced death [34,50] suggesting inactivation of
Rb and activation of the cell cycle in these neurons.
Additionally, increase in E2F1 (downstream effector of
Cdk4) protein levels and proliferating cell nuclear antigen
(PCNA) another S-phase marker (required for completion of
DNA synthesis and repair) is observed following KA induced
death [48,51]. Finally, increase in E2F1 mRNA transcript is
also observed following OGD [52]. These observations
discussed above seem to implicate the reactivation of cell
cycle machinery in ischemic neuronal death and have lead to
the hypothesis that inappropriate activation of the cell cycle in
the context of differentiated neurons may underlie ischemic
neuronal death. However, this evidence only showed the
activation of cell cycle components and does not address the
issue of whether this signal is required for death. In other
words, does the activation of the cell cycle in adult neurons
underlie neuronal death in stroke or are these observations
simply an artifact of the cell death process? Studies using
pharmacological inhibitors of cell cycle regulators seem to
lend support to the former. For example, treatment of neurons
with the CDK inhibitors olomoucine, roscovitine, 3-amino
thioacridone (3-ATA) and flavopiridol has been shown to
protect cortical neurons and CGNs from OGD and KA
induced cell death [42,47,51,53]. While these pharmacological
studies supports the involvement of cell cycle components in
ischemic neuronal death, the caveat to these studies is the
relatively non-specific nature of inhibitors such as flavopiridol
which in addition to the cell cycle CDKs can potently inhibit
non-mitotic CDKs such as cdk5 [54], cdk7 [25] as well as
non-CDK-related kinases such as GSK-3β [55]. To address
this, the functional relevance of cell cycle machinery in
ischemic neuronal death was demonstrated by utilizing genetic
manipulations of components of the cell cycle. Firstly,
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dead cdk4 protects CGNs from hypoxia mediated delayed
death. Secondly, they showed that neurons derived from mice
expressing kinase dead cdk4 or null for its regulator cyclin D1
are resistant to hypoxia mediated ischemic death [34]. Further
support for the functional role of cell cycle pathway in
ischemic neuronal death is provided by observations thatTable 1
Correlative evidence for the involvement of cell cycle components in stroke models
Component In vitro In vivo
Model Effect References Model
Cyclin D1 OGD Increased level [42] MCAO
Focal cereb
Global Isch
KA injectio
Spinal cord
Cardiac arr
Cyclin E KA Increased level [48]
Cyclin A MCAO
Cyclin H Global isch
Cyclin G1 MCAO
Global isch
Spinal cord
CCAO and
Cdk4 MCAO
Focal cereb
Global Isch
KA injectio
Spinal cord
Cardiac arr
Cdk2 OGD Activated [42] MCAO
KA Increased level [48] Hypoxia–is
MCAO
Cardiac arr
p16 MCAO
Hypoxia–is
p21 MCAO and
p27 OGD Loss [42] Hypoxia–is
Rb Hypoxia Phosphorylation [34] MCAO
KA Phosphorylation [50] Global isch
Hypoxia–is
KA injectio
E2F1 OGD Increased mRNA [52] Focal cereb
KA Increased level [48,51] Global isch
PCNA KA Increased level [51] MCAO
Global isch
Brdu MCAO
Hypoxia–is
Cdk5 MCAOcortical neurons and CGNs derived from E2F1 null mice are
less susceptible to death mediated by OGD and KA induced
death respectively [50,52]. Furthermore, E2F1 deficiency
improves the recovering of CA1 neurons from loss of synaptic
transmission following anoxic insult of hippocampal slices in
vitro [52]. The above in vitro evidence is summarized in
Tables 1 and 2.Effect References
Increased level [42,56–58]
ral ischemia Increased level [32]
emia Increased level [59–63]
n Increased level [61,64–66]
ischemia Increased level [67]
est Increased level [86]
Increased level & nuclear localization [70]
emia Increase level in resistant neurons [87]
Increased level [71]
emia Increased level [72]
injury Increased level [92]
MCAO Increased level & nuclear translocation [93]
Increased level [68]
ral ischemia Increased level [32]
emia Increased level [63]
n Increased level [66]
ischemia Increased level [67]
est Increased level [86]
Increased activity [42]
chemia Increased activity [69]
Increased level & nuclear translocation [70]
est Increased level [86]
Decreased level [42]
chemia Decreased level [69]
global ischemia Increase level in surviving neurons [71–73]
chemia Decreased level [69]
Phosphorylation [32,58,78]
emia Phosphorylation [33,34]
chemia Phosphorylation [69]
n Phosphorylation [65]
ral ischemia Increased level [32]
emia Increased level [81,82]
Increased level [58,70]
emia Increased level [63,84]
Incorporation in neurons [58]
chemia Incorporation in neurons [69]
Increased level [108]
Table 2
Functional evidence for the involvement of cell cycle components in stroke models
Component In vitro In vivo
Model Method; effect References Model Method; effect References
Genetic studies
Cyclin D1 Hypoxia Null mutant neurons protective [34] KA injection Antisense; protective [66]
Cdk4 Hypoxia Dominant negative expression; protective [34] MCAO Synthetic inhibitor; protective [58]
KA injection Antisense; protective [66]
Global ischemia Dominant negative expression; protective [34]
E2F1 OGD Null neurons; protective [52] Focal cerebral ischemia Null mice; resistant [79,80]
KA Null neurons; protective [50]
Anoxia Null mutant hippocampal slices; protective [52]
Cdk5 Global ischemia Dominant negative expression; protective [34,109]
Pharmacological studies
Flavopiridol KA Protective [51] Focal cerebral ischemia Protective [32]
KA Protective [47] Global ischemia Protective [33]
Olomucine KA Protective [53]
OGD Protective [42]
Roscovitine KA Partial protection [53]
3-ATA KA Protective [47]
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reactivation of cell cycle components in ischemic neuronal
death. What evidence is there to implicate the involvement of
cell cycle machinery in vivo? Are these observations relevant in
intact physiological systems?
5. In vivo evidence for involvement of cell cycle elements in
stroke
The above evidence indicates that neurons grown in culture
can re-activate cell cycle signals upon an exogenous stress
leading to death. This suggests that terminally differentiated,
post mitotic neurons from embryonic or early post natal sources
have retained their capacity to reactivate cell cycle CDK
mediated signals. However, these neurons have only recently
become post-mitotic and might represent a unique situation
where the cell cycle machinery is still present. Indeed, reports
have shown that while downregulated, multiple CDKs, cyclins
as well as their regulators exist in cultured neurons [36,37].
Questions remain about the more relevant situation where
ischemic injury occurs in fully matured adult neurons where
there is likely very little if any cell cycle machinery present
under basal conditions. Here too, there is accumulating
evidence that upregulation/activation of cell cycle machinery
occurs and this leads to death in neurons following stroke insult.
The first body of work linking cell cycle to ischemic injury in
the adult context is the correlative data demonstrating that
CDKs are changed following stroke injury in vivo. In these
situations, a central player may again be the cdk4–cyclin D
complex. For example, Cdk4/6 kinase activity/levels along with
its activator cyclin D1 are upregulated in different models ofischemia in vivo. It has been shown that cyclin D1 is expressed
in infarct region following MCAO model of focal ischemia
[32,42,56–58] and in vulnerable regions of the hippocampus
following transient global ischemia [59–63]. Consistent with
these observations, increased levels of cyclin D1 has been
demonstrated in response to an excitotoxic death induced by
systemic injection of KA [61,64–66] and transient spinal cord
ischemia [67]. Cdk4 itself is also changed during ischemic
insult. Aberrant expression of cdk4 has been shown in MCAO
[68] and clip models of focal ischemia [32]. Furthermore, other
groups have reported induction of cdk4 expression in other
models such as transient global ischemia [63], KA-mediated
cortical death [66] and transient spinal cord ischemia [67].
Although the above evidence implicates cyclinD1–cdk4
complexes in ischemic injury, it must be kept in mind that other
components of G1 phase might have potential roles in vivo as
well. For instance, cdk6 is also activated by cyclin D [17]. In
addition, there are some lines of data suggesting deregulation of
cdk2 after MCAO and a hypoxic cerebral ischemia [42,69].
Consistent with this, Li et al. [70] provided evidence that cdk2,
as well as its partner, cyclin A, are deregulated following focal
ischemia.
In line with the upregulation/activation of cell cycle CDK
complexes, evidence also point to a modulation of endogenous
regulators of CDKs, the CDKIs. For example, Katchanov et al.
[42] demonstrated that p16 is downregulated very early in dying
neurons, followed by upregulation of cyclin D1 after a mild
cerebral ischemia. Additional intriguing observations suggest-
ing that CDKIs might have a functional role in ischemic death
were provided by Van Lookeren et al. [71,72]. They indicated
that p21 expression is enhanced in surviving neurons
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ischemia. They suggested that elevation of p21 is actually a
response to the ischemic insult to protect the neurons by
arresting them in first steps of the cell cycle. In line with these
findings, p21 mRNAwas elevated in perifocal ischemia regions
following focal ischemia, while no significant change was
observed in ischemic area [73]. More importantly, Kuan et al.
[69] demonstrated that p16 and p27 are depleted in dying
hippocampal neurons and this may promote G1/S phase
transition following hypoxia–ischemia insult.
The above mentioned in vivo evidence does not indicate
whether these signals actually play a role in ischemic damage.
To address this, several labs, including ours, have provided
more direct data by carrying out additional functional studies. In
support of a require role, inhibition of the cell cycle regulating
proteins is protective in some of the ischemic models. For
instance, administration of a synthetic cdk4 inhibitor, or
alternatively, cyclin D1 and cdk4 antisense oligonucleotides
has been shown to be neuroprotective in MCAO and KA-
inducing excitotoxicity models, respectively [58,66]. We have
recently shown that flavopiridol, a CDK inhibitor, administrated
before or after the insult, blocks the delayed death evoked by
focal or global ischemia [32,33]. Importantly, flavopiridol
blocked activation of the cdk-Rb pathway, reduced E2F1 levels
and improved behavioral performance [32,33]. More critically,
we also investigated involvement of specific CDKs by
expression of kinase dead dominant negative forms of several
cell cycle CDKs, as well as cdk5, in delayed and excitotoxic
types of ischemia. In this research for the first time we provided
functional evidence that in adult system, cyclin D1–cdk4
complex has a key role in inducing delayed neuronal death [34].
We also showed that phosphorylation of Rb, mediated by this
complex, occurs very early following global ischemia and that
this activation is inhibited by DN cdk4 expression [34].
Expression of DN cdk4 also improves behavioral performance
in rats suggesting that brains are not only neuroprotected, but
that this leads to improved function [34]. This final point is
particularly relevant to the goal of human therapy.
How do cyclin–CDK complexes mediate a potential
ischemic death signal, in vivo? In other words, what is (are)
the downstream target(s) for these complexes in adult systems?
Recent findings suggest that inactivation of Rb leads to
neuronal apoptosis, in vivo. Supporting this, overexpression
of large T antigen in cerebellar Purkinje cells initially resulted in
DNA synthesis but eventually caused neuronal degeneration in
transgenic mice [74]. Rb deficiency is also embryonically lethal
because of widespread apoptosis in CNS and PNS [75,76].
However, in this case, much of the death may be due to non-
neuron autonomous events and not directly caused by Rb
deficiency [77]. Observations in different in vivo models of
ischemia have suggested that CDKs activity induced by
apoptotic insults lead to phosphorylation and inactivation of
Rb. For example, we have shown that Rb phosphorylation (on
ser-795, a consensus site for CDKs) is an early that event
happens a few hours after focal ischemia [32], global ischemia
[33,34] and KA injection [65]. Moreover, other groups have
also shown that Rb is progressively phosphorylated at CDKsconsensus sites after focal ischemia induced by MCAO and
hypoxic cerebral ischemia and that this might trigger apoptotic
neuronal death pathways [58,69,78].
To investigate the mechanism by which Rb inactivation
may promote death, E2F family proteins, as a group of
proteins regulated by Rb, have been studied in vivo. In this
regard, it has been suggested that E2F may play an important
role in neuronal death in select conditions such as stroke. For
example, E2F1 deficient mice has been shown to exhibit
smaller brain injury and improved behavior after focal
ischemia [79,80]. In agreement with this, upregulation of
E2F1 has been implicated in animal models of ischemia. For
instance, we have shown that focal ischemia induces E2F1
expression which occurs following Rb phosphorylation and
administration of CDK inhibitor diminishes this effect and
protects the neurons [32]. Microarray analysis also has also
revealed that E2F1 is among the upregulated genes after
global ischemia [81]. Finally, a very recent study demon-
strated that E2F1 and its target gene, c-myb, is upregulated in
hippocampus following global ischemia [82]. What factor(s)
determine which responsive genes, whether cell cycle or
apoptotic, be regulated? It is not clear yet, but there is an idea
suggesting that there is a pool of transcriptional activity for
E2F. When this activity gets to a specific threshold the genes
regulating cell cycle progression are induced. But when this
activity reaches a second higher threshold, apoptotic genes are
induced and death mechanisms start [83]. Almost nothing is
known about the targets of E2F1 in ischemic death, in vivo,
and this area needs to be intensively investigated.
Although what has been discussed so far suggests that cell
cycle is aborted mostly at G1/S checkpoint in ischemic death,
some reports have shown S phase entry. Indeed, neurons start to
replicate DNA before they die in some systems. To investigate
whether DNA synthesis is induced in dying neurons, induction
of PCNA and incorporation of Brdu have been used as markers
for S phase. In this regard, induction of PCNA has been
demonstrated in several models of focal and global ischemia
[58,63,70,84]. In other reports, incorporation of Brdu in
apoptotic neurons is indicative of tendency for DNA synthesis
in these cells [58,69]. Interestingly, these injured, “S phase
positive” neurons contained elevated G1 cyclin–CDK com-
plexes and co-localized with apoptotic markers (TUNEL
positive); suggesting that cell cycle is already triggered and
they have transited to S phase to resume DNA synthesis but for
some reasons they undergo apoptosis and do not replicate.
Therefore, there is no in vivo evidence of G2 entry in ischemic
neurons, to our knowledge. Nevertheless, expression of cdc2, as
E2F target and a G2 marker has been investigated in other
neuronal death systems [85]. This might be an important area of
future research in the stroke field.
In spite of the accumulating in vivo experimental studies
demonstrating aberrant deregulation of cell cycle in stroke,
there is little known about how/whether these processes occur in
humans. Recently, a group investigated cell cycle elements in
brains of postmortem patients who died after cardiac arrest or
focal brain infarction. They reported elevated levels of cyclin
D1, cdk2 and cdk4 [86]. This study shows that results obtained
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human condition.
The in vivo evidence discussed above is summarized in
Tables 1 and 2.
6. Role of other CDK members including cdk5 in stroke
In addition to the core cell cycle components discussed
above, other cyclins and CDK members which are not
exclusively or fully linked with cell cycle regulation may also
participate in ischemic response. For example, cyclin H, a
component of the CAK complex is increased in CA3, dentate
gyrus, and cortex after global ischemia [87]. Since these
areas are resistant to this type of ischemia, it has been
suggested that cyclin H might have a role in survival through
its DNA repair function in ischemic injury. Cyclin G is
another member of the cyclins family but its role in cell cycle
is controversial. While some evidence shows its stimulating
role in growth [88,89], others suggesting it inhibits growth
[90,91] in proliferating cells. The function of cyclin G in
neurons is also unclear. Nevertheless, it has been shown that
cyclin G1 is increased following MCAO and global ischemia
[71,72], as well as spinal cord injury [92]. Furthermore,
Maeda et al. [93] demonstrated that cyclin G1 is translocated
into the nucleus of degenerating neurons following transient
common carotid artery occlusion (CCAO) and MCAO.
Therefore, they suggested that the cytoplasmic cyclin G1
might be associated with cell survival while nuclear cyclin
G1 might signal death.
Perhaps the strongest evidence for the involvement of a
CDK member not classically associated with the cell cycle
involves cdk5. Cdk5 is a unique member of cyclin-dependent
kinases family. Unlike the other CDKs, it does not require a
cyclin to be activated. P35 and p39, instead, are activators of
cdk5 and are present mainly in neurons [94,95]. For this
reason, although is ubiquitously expressed, cdk5 activity is
mainly restricted to nervous system [96]. Even though there is
no functional evidence for involvement of cdk5 directly in the
core cell cycle machinery, some recent observations have led
to the idea that it might be associated with cell cycle
components and, therefore, affects its transition. Initially it
was shown that cdk5 was able to bind to cyclins D1, D3 and
E [97–99]. However, this binding did not lead to increased
CDK activity. Further studies showed that cdk5 could
phosphorylate Rb in vitro [100]. In this study, overexpression
of p25 in inducible neuroblastoma cells led to deregulation of
cell cycle elements such as elevation of cyclins A and B1 and
cdc2, downregulation of p27 and finally apoptosis. Interest-
ingly, Rb phosphorylation on ser807/811 sites was an early
event in this study and was mediated by cdk5 activity since it
was abolished by a cdk5 inhibitor [100]. Finally, a very recent
report revealed that cdk5 is necessary for neuronal cell cycle
arrest [101]. This group suggested that cdk5 connects and
inhibits cell cycle possibly by competing with cdk4/6 for
binding to cyclins or through a kind of phosphorylation of Rb
that inhibits E2F or, alternatively, by phosphorylation of RNA
polymerase.Cdk5 has been implicated in different neurodegenerative
disorders including brain ischemia. The generally accepted
concept about cdk5 is that cdk5/p35 complexes are regulators of
normal biological functions of neuron. But under some
neuropathological conditions p35 is cleaved to a more potent
activator, p25 [102]. Production of p25 unmasks pathological
face of cdk5 since it has prolonged half life, over activates,
dislocates and might change cdk5 substrate specificity. There is
increasing evidence, though, that argue this model. Several
studies have debated role of p25 in pathogenecity of cdk5 in
some circumstances [103–107]. While an exhaustive review of
this issue is not possible here, we will suggest that, depending
upon different factors; both p35 and p25 are able to drive “good-
normal” cdk5 to “bad-pathogenic” cdk5.
Contribution of cdk5 in stroke has not been intensively
studied and our knowledge about desregulated cdk5 in stroke
comes from very recent research. One of the initial reports came
from Hayashi et al. study [108]. They showed that immunor-
eactivity of cdk5 and p35/p25 is enhanced in MCAO model.
Likewise, we [34] as well as Wang et al. [109] , have recently
provided evidence that cdk5 is a mediator of excitotixc neuronal
death in global and focal ischemia.
Similar to classic cell cycle CDKs, the important question of
the mechanism by which aberrant cdk5 causes neuronal damage
remains. Several possibilities may exist. For example, it has
been reported that cdk5 can phosphorylate the NMDA receptors
regulating calcium influx [109]. Interestingly tau, a micro-
tubule-associated protein which is connected to Alzheimer's
disease pathology, has also been recently shown to be as a
substrate for cdk5 following ischemia [110]. What this means is
unknown, however. There might also be other candidates such
as MEF2 (Myocyte Enhance Factor-2) or p53 transcription
factors. Both have been shown to be regulated by cdk5 and both
have been implicated in ischemic/excitotoxic death [111–113].
However, the link between cdk5 and these factors have not been
yet addressed in in vivo stroke studies.
7. Conclusion
As summarized above, there is increasing evidence of the
involvement of multiple cell cycle regulatory signals in
ischemic injury. Several important questions remain however,
and include: 1) What are the mechanism(s) by which cell cycle
signals are actually activated following stroke injury; 2) Are
there other mechanisms by which cell cycle CDKs may impact
death other than through modulation of Rb; 3) Does cdk5
regulate cell cycle signals in models of stroke 4) Are cell cycle
targets in and of themselves a viable therapeutic option for
stroke.
The latter question is of particular importance since most
pharmacotherapeutic strategies tested in the clinic for treatment
of stroke have failed. One reason for this is likely that
preclinical testing in animal models has not been sufficiently
stringent prior to clinical trials. In this regard, vigorous
benchmarks of (a) efficacy of any strategy in multiple animal
models, (b) behavioral and functional improvements beyond
neuroprotection and (c) long lasting efficacy have been
491J. Rashidian et al. / Biochimica et Biophysica Acta 1772 (2007) 484–493established. Cell cycle inhibitors appear to at least meet some of
these criteria. For example, the CDK inhibition has been shown
to be neuroprotective in multiple models and lead to improved
behavior/function. However, the CDK inhibitor flavopiridol, at
least, seems to lack long term efficacy. This may be due to the
non-selective nature of flavopiridol or and indication that CDK
inhibition by itself cannot completely normalize neuron
function. These issues will have to be carefully addressed
before CDK inhibitors can be contemplated for future clinical
trials.
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